Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Mapping TMS‑induced light flashes (phosphenes) while tracking eye movements

Official title: Study of Visual Perception Phenomena: Phosphene Mapping Induced by TMS and Its Relationship With Eye Movements

Run by Skolkovo Institute of Science and Technology · NCT07110493 · Data updated 2026-11-12

Researchers will test whether single‑pulse TMS produces brief light flashes and how eye movements change where adults with visual snow, color blindness, and healthy volunteers see those flashes.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment50 (estimated)
SponsorSkolkovo Institute of Science and Technology
Academic / other
Locations1 site (Moscow)
StatusRecruiting
StartedSeptember 10, 2025
Main results expectedDecember 10, 2026
Study endsDecember 10, 2026
Registry record updatedAugust 7, 2025
Trial IDNCT07110493 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 18–65 with a confirmed diagnosis of visual snow syndrome, adults with a documented color vision disorder, or healthy adults without past or active neurological, psychiatric, or ophthalmological disorders.

Probably not a fit

People with active neurological, psychiatric, or ophthalmological conditions outside the defined groups, or those who cannot undergo or tolerate TMS, EEG, or eye‑tracking, are unlikely to receive direct benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants aged 18–65 will receive single‑pulse transcranial magnetic stimulation (TMS) to visual cortex while wearing an eye‑tracker and EEG cap and reporting where brief phosphenes appear. The study enrolls three groups: people with visual snow syndrome, people with diagnosed color vision disorders, and healthy controls. Researchers will map relationships among stimulation site, eye position, and reported phosphene location to see how gaze shifts affect perceived location. Results aim to clarify basic mechanisms of visual perception and improve methods for mapping cortical visual responses.

Why it matters

Potential benefit: If successful, this work could improve understanding of how eye movements alter perceived visual signals and lead to better methods for mapping visual cortex responses that may inform diagnostics or rehabilitation approaches.

How similar studies have gone: Previous basic research has shown TMS can elicit phosphenes and that eye position influences perceived location, but combining TMS with simultaneous eye‑tracking and EEG across these clinical groups is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

For the "Patients with Visual Snow Syndrome" Arm:

Confirmed diagnosis of Visual Snow Syndrome according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria.

Presence of persistent, dynamic, tiny dots ("visual snow") across the entire visual field.

Presence of at least one of the following additional visual symptoms:

Palinopsia (prolonged afterimages). Photophobia (hypersensitivity to light). Nyctalopia (impaired night vision). Blurred vision. Patients whose symptoms appeared after a SARS-CoV-2 viral illness may be included.

For the "Color-blind Participants" Arm:

Presence of a color perception disorder. Must have a formal diagnosis of color blindness confirmed by specific ophthalmologic tests (e.g., Ishihara, Rabkin, Justova, or Stilling polychromatic plates, or the Farnsworth-Munsell test).

For the "Healthy Controls" Arm:

Absence of any active or past neurological, psychiatric, or ophthalmological disorders.

Exclusion Criteria:

General Criteria (Applicable to all participants):

Use of psychotropic drugs. Any contraindications to Transcranial Magnetic Stimulation (TMS), such as a history of epilepsy, seizures, or metallic implants in the head.

Pregnancy.

Specific to the "Patients with Visual Snow Syndrome" Arm:

Presence of any organic abnormalities in the eyes or visual system identified during a standard ophthalmologic examination.

Presence of comorbid psychiatric disorders or other medical conditions (e.g., migraine with aura) that could explain the symptoms.

Specific to the "Color-blind Participants" Arm:

Any non-congenital cases of color blindness. Presence of concomitant visual impairments that could affect visual perception independently of color blindness, such as cataracts, glaucoma, or macular degeneration.

Presence of concomitant neurological or psychiatric diseases, such as schizophrenia, epilepsy, or mood disorders, that could affect the study results.

Where it's running

  • Skolkovo Institute of Science and Technology (Skoltech)
    Moscow, Russia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.